Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Instil Bio, Inc. (NQ:TIL)

7.035 +0.245 (+3.61%)
Delayed Quote Updated: 1:41 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Instil Bio, Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
From Instil Bio
Via GlobeNewswire
News headline image
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024 ↗
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023 ↗
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside ↗
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments. 
Via Benzinga
News headline image
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? ↗
This drugmaker's lead candidate could become a top-selling cancer therapy. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
2 Stocks Up Over 700% in 2024 That Could Soar Even Further ↗
These relatively small companies are developing new cancer therapies that could generate billions in annual sales. 
Via The Motley Fool
News headline image
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023 ↗
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2023. 
Via InvestorPlace
News headline image
Steelcase Reports Weak Sales, Joins American Healthcare REIT And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Here's Why Everyone's Talking About Summit Therapeutics ↗
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock. 
Via The Motley Fool
News headline image
Crude Oil Surges Over 1%; Instil Bio Shares Plunge ↗
 
Via Benzinga
News headline image
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
From Instil Bio
Via GlobeNewswire
News headline image
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? ↗
A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy. 
Via The Motley Fool
News headline image
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal ↗
Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million,... 
Via Talk Markets
News headline image
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
From Instil Bio
Via GlobeNewswire
News headline image
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday 
Via InvestorPlace
News headline image
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024 ↗
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Announces Strategic Update
From Instil Bio
Via GlobeNewswire
News headline image
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023 ↗
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2023. 
Via InvestorPlace
News headline image
TIL Stock Earnings: Instil Bio Misses EPS for Q3 2023 ↗
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the third quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.